FEMY Femasys Inc
Company Analysis
Latest News
🔴 Femasys is trading 10.68% down in pre-market after an August 19 rally
Femasys is trading at $2.42, down -10.68%, following a sharp August 19 rally after the FDA approved a modular PMA pathway for FemBloc. - The decision allows...
Femasys Gets a Regulatory Green Light for Its Birth-Control Device — But Can a $8 Million Company Turn Paperwork Into Profits?
Shares of Femasys (FEMY) sank -7.7% to $2.50 in pre-market trading on August 20, one day after a euphoric rally that saw the stock spike as high as $3.69...
🔴 Femasys is trading 7.75% down in pre-market after profit-taking following FDA’s modular PMA pathway approval
Femasys is trading at $2.50 (-7.75%) in pre-market on August 20, 2026, with weakness appearing to reflect profit-taking after FDA approval of a modular PMA...
🔴 Femasys is trading 6.27% down in after-hours trading amid apparent profit-taking after FDA pathway approval
Femasys is trading at $2.54, down 6.27%, with the after-hours decline appearing to reflect profit-taking after the FDA approved a modular PMA pathway for...
Femasys Wins FDA Rolling Review for FemBloc, Expediting Approval Path
Femasys Inc. received FDA approval for a modular premarket approval (PMA) submission for its FemBloc permanent birth control device. This allows the company to...
🟢 Femasys is trading 24.05% up today after positive Moderna and Merck melanoma-vaccine results
Femasys is trading 24.05% up now at $2.73, primarily as biotechnology shares rallied after positive Moderna and Merck Phase 3 melanoma-vaccine results. - The...
🔴 Femasys is trading 5% down today after Q2 sales fell 18.9% year over year
Femasys is trading 5% down at $2.17 after investors digested the August 14, 2026 quarterly results, with Q2 sales falling 18.9% year over year to $331,827...
Femasys second quarter 2026 revenue of $0.33M missed estimates significantly despite subsequent $30M financing
Femasys reported a substantial miss on top and bottom-line results for the second quarter 2026, with revenue declining nearly 19% year-over-year. The results...
🔴 Femasys is trading 5.5% down today as $30 million placement raises dilution concerns
Femasys is trading at $2.22, down -5.53%, as its announced $30 million private placement raises dilution concerns. - The financing includes shares and...
Femasys Inc Q2 2026 Earnings Preview: What Analysts Expect on August 14, 2026
Analysts expect Femasys Inc to report a consensus revenue of $1.68 million and a net loss per share of $0.10 for the second quarter, while the current stock...
Femasys Locks Down Key Patents and Fresh Cash — But Can a Micro-Cap Birth Control Startup Translate IP Into Revenue?
Shares of Femasys jumped 14% to $2.68 after the Atlanta-based women's health company disclosed new U.S. and international patents covering the core...
🟢 Femasys is trading 14% up today in after-hours trading after new U.S. and international FemBloc patents
Femasys is trading at $2.68, up +13.96% after announcing new U.S. and international patents protecting FemBloc’s blended-polymer component on August 12,...
🟢 Femasys is trading 6.6% up today with no company-specific catalyst identified
Femasys is trading 6.6% up at $2.50, amid a stronger broader market, with no new company-specific announcement explaining the August 12, 2026 move...
🟢 Femasys is trading 5.1% up in pre-market with no clear catalyst identified
Femasys is trading 5.1% up at $2.47, with no company-specific announcement identified to explain the pre-market rebound. - It closed at $2.35 on August 11,...
🟢 Femasys is trading 7.87% up in after-hours trading — no company-specific announcement identified
Femasys is trading 7.87% up at $2.53 after closing at $2.35 on August 11, 2026; no new company-specific announcement explaining the after-hours rebound was...
🔴 Femasys is trading 10.9% down today after $30 million placement raised dilution concerns
Femasys is trading 10.9% down now at $2.37 as investors continue reacting negatively to the $30 million private placement announced August 7, 2026. -...
🔴 Femasys is trading 5.6% down today as investors continue reacting negatively to $30 million placement
Femasys is trading 5.6% down now at $2.51 as investors continue reacting negatively to the $30 million private placement announced August 7. - The deal...
🟢 Femasys is trading 6.77% up today after initial negative reaction to $30 million financing
Femasys is trading at $2.84, up 6.77%, as it rebounds after investors initially reacted negatively to the financing announcement. - The $30 million private...
🔴 Femasys is trading 5% down in pre-market after $30 million private placement with warrants
Femasys is trading 5.26% down now at $2.52 after investors reacted to its $30 million private placement announced on August 7, 2026. - The financing includes...
Femasys Raises $30 Million in a Dilution-Heavy Deal — Can a Micro-Cap Women's Health Company Grow Fast Enough to Justify the Pain?
Shares of Femasys cratered 15.3% to $2.50 after the company announced a $30 million private placement that could flood the market with new stock. For a company...